Interesting RVMD Put And Call Options For May 15th

Revolution Medicines (RVMD) trades at $98.21 and the article analyzes two option strategies: selling a $90 put (bid $6.60) which would set an effective purchase basis of $83.40 and is assessed to have a 68% chance of expiring worthless, producing a 7.33% yield on cash (25.50% annualized). The covered-call example sells a $105 call (bid $9.10) against a $98.21 long position, offering a 16.18% total return to assignment with a 50% chance of expiring worthless and a 9.27% immediate yield boost (32.22% annualized); implied volatilities are ~63% (put) and 62% (call) versus trailing 12‑month volatility of 55%.

Analysis

MARKET STRUCTURE: The option chain around RVMD ($98.21) reveals symptomatic demand for entry via put selling and income via covered calls — the $90 put offers $6.60 premium (net basis $83.40) and the $105 call offers $9.10 on a long position, with May 15 expiry ≈3.5 months out. Implied vol (62–63%) sits ~7–8 pts above trailing realized vol (55%), signaling a modest volatility risk premium that benefits option sellers while providing a hedge for holders against rapid repricing. Net effect: short-dated income trades win if biotech sector remains benign; binary clinical/regulatory shocks hurt option sellers and concentrated equity holders.

RISK ASSESSMENT: Tail risk is idiosyncratic and binary — a negative clinical readout or FDA action could spike IV >150% and push RVMD well below the $90 strike, exposing put-sellers to >15% immediate mark-to-market and larger downside. Short-term (days–weeks) risk is IV/gamma exposure; medium-term (to May 15) is assignment probability (puts ~32% chance ITM per current odds); long-term depends on fundamentals (trial readouts, partnerships) and could materially re-rate valuation. Hidden dependencies include option liquidity, skew, and sector contagion (XBI/IBB flows) that can amplify moves.

TRADE IMPLICATIONS: If comfortable owning RVMD, sell the May 15 $90 put sized ≤1–2% portfolio per contract (synthetic purchase at $83.40) or implement a put-credit spread (sell $90 / buy $80) to cap tail losses; target realized yield ~7.3% over ~3.5 months, exit on 50% premium capture or IV spike >100%. For upside seekers, buy shares and sell May $105 calls to collect ~9.3% boost (cap at 16.2% total if called); alternatively, buy a 3–6 month call-debit spread ($100/$120) if asymmetric upside is sought without full equity exposure. Use position sizing limits and close or hedge if RVMD gaps >10% intraday.

CONTRARIAN ANGLES: The market is underpricing binary downside — selling naked puts assumes clinical/regulatory noise remains low; that consensus is fragile given historical biotech blow-ups where IV re-prices rapidly. Conversely, modest IV premium vs realized suggests income strategies are not fully compensated for tail risk; there may be mispricing in short-dated puts versus longer-dated protection. Historical parallels (small-cap biotech before late-stage readouts) show income harvesting works until a single event reverses it, so cap exposure and prefer spreads over naked short puts.

Key Decisions for Investors

• Establish a limited-size (1–2% portfolio) position by selling May 15 RVMD $90 puts at $6.60, or preferably sell a $90/$80 put-credit spread to cap tail risk; target 50% premium capture to exit or accept assignment (basis $83.40) and hedge with a 3–6 month protective collar if assigned.
• If bullish on RVMD's fundamentals, buy shares at market and sell May 15 $105 covered calls to collect $9.10 (expected capped total return ~16.2% to May 15); size to no more than 2–3% portfolio and roll or buy back if share rises >10% before expiry.
• Avoid naked short puts >2% exposure and monitor IV and bid/ask spreads: close or hedge positions if RVMD IV >100% or if the stock gaps >10% intraday; place hard stop-loss at 15% adverse move from entry to limit tail losses.
• Relative-value: take a long RVMD / short XBI position (equal dollar) if you expect idiosyncratic upside from RVMD versus the sector over the next 3–6 months; size modestly (1–2% net) and hedge with OTM puts on RVMD (buy $80) to protect against sector shock.
• Watch catalysts: next 30–90 days — specific trial readouts, FDA communications, or partnership announcements; refrain from initiating or expand positions within 10 trading days before/after those events unless using defined-risk option structures.